echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA latest: Over 50% of Chinese adults have diabetes or are in the pre-disease period!

    JAMA latest: Over 50% of Chinese adults have diabetes or are in the pre-disease period!

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎Non-communicable diseases, such as diabetes, tumors, and cardiovascular diseases, are the most important causes of death in the global population, and their prevention and control are also important public health challenges facing the world
    .

    As one of the most important non-communicable diseases that threaten the health of the global population, the number of diabetes patients worldwide is increasing rapidly and the incidence is showing a steady upward trend
    .

    According to statistics, the prevalence of diabetes in China has risen from less than 1% during 1980 to around 11% in 2013, and it has become the country with the largest number of diabetes patients in the world
    .

    So since 2013, how has the prevalence and treatment of diabetes in China changed? On December 28, 2021, the Journal of the American Medical Association (JAMA) published the latest statistics on diabetes prevalence and treatment in China from 2013 to 2018
    .

    According to the results of this survey, the prevalence of adult diabetes in China rose from 10.
    9% in 2013 to 12.
    4% in 2018; the prevalence of pre-diabetes rose from 35.
    7% in 2013 to 38.
    1% in 2018
    .

    In general, the overall prevalence of diabetes in China is not only high and showing an increasing trend, but at the same time the proportion of patients receiving adequate treatment has not been significantly increased
    .

    The paper pointed out that the current study is based on a large number of samples (170,287 and 173,642 subjects were included in the final analysis in 2013 and 2018), and it provides the latest statistics on the prevalence, treatment level, and risk factors of diabetes in China
    .

    The corresponding authors of the study are Professor Wu Jing from the Chronic Disease Center of China CDC and Professor Wang Youfa from the Institute of Global Health, Xi’an Jiaotong University
    .

    Screenshot source: JAMA China Chronic Disease and Risk Factors Surveillance (China Chronic Disease and Risk Factors Surveillance) study is an ongoing, periodic, nationally representative cross-sectional survey
    .

    The last two large-scale surveys were carried out from June 2013 to May 2014 and August 2018 to June 2019, and included 179347 and 184509 subjects respectively
    .

    The data of the current investigation and research on diabetes prevalence and treatment in China are derived from the above-mentioned research
    .

    The main outcome of the study was the prevalence of diabetes and prediabetes; the secondary outcome was the awareness rate of diabetes, treatment rate, control rate, and prevalence of disease risk factors
    .

    The results of the study show that according to the survey data of 173642 subjects (median age 51.
    3 years) finally included in the analysis, the overall prevalence of diabetes in 2018 was approximately 12.
    4%, pre-diabetes prevalence was approximately 38.
    1%, diabetes and pre-diabetes The total prevalence rate has exceeded 50%! In contrast, among the 170,287 subjects included in the analysis in 2013, the overall prevalence of diabetes was approximately 10.
    9%, and the pre-diabetes prevalence was approximately 35.
    7%
    .

    In 2018, the awareness rate of diabetes was 36.
    7%, the treatment rate was 32.
    9%, and the control rate was 50.
    1%.
    These data are not significantly different from 2013
    .

    This shows that from 2013 to 2018, the awareness rate, treatment rate and control rate of diabetes in China were still at a low level
    .

    While the prevalence of diabetes in China is high and growing, the proportion of patients receiving appropriate treatment has not increased significantly
    .

    There are differences in the prevalence and treatment of diabetes in different genders, ages and places of residence
    .

    Specifically, the prevalence of diabetes in women was significantly lower than that in men (in 2013 and 2018, 10.
    2% vs 11.
    7%, 11.
    5% vs 13.
    3%), and the treatment rate of diabetes in women was also higher than that in men in the two surveys The prevalence of diabetes increases with age (in 2013, the prevalence rate was 5.
    0% for 18-29 years old, and 20.
    7% for ≥79 years old; in 2018, the prevalence rate was 5.
    0% for 18-29 years old, and 27.
    3 for ≥79 years old.
    %)
    .

    (Click on the picture to view the larger picture) ▲Awareness, treatment and control rate of diabetes in adults in China-data from 2013 and 2018 (picture source: reference [1]) And treatment results may be affected by many factors, such as behavioral factors (including smoking, dietary intake, sedentary life>
    .

    In the past 20 years, the obesity rate of the Chinese population has increased rapidly.
    It is estimated that by 2030, the overweight/obesity rate of the Chinese population will reach 65.
    3%
    .

    Current research also found that the incidence of overweight/obesity is significantly related to the overall population’s unhealthy life>
    .

    Specifically, between 2013 and 2018, the proportion of current smokers dropped from 27.
    5% to 26.
    0%; the proportion of excessive drinking dropped from 9.
    3% to 8.
    2%
    .

    At the same time, the proportion of red meat intake increased from 32.
    6% to 42.
    3%; the proportion of insufficient physical exercise increased from 16.
    0% to 22.
    0%; the overweight rate increased significantly from 32.
    5% to 34.
    5%; the obesity rate increased from 14.
    1% to 16.
    5 %; the rate of central obesity increased significantly from 31.
    6% to 35.
    4%
    .

    Due to the large number of pre-diabetic populations, combined with the general changes in people's life>
    .

    ▲Diabetes-related risk factors for Chinese adults, such as changes in residence, education level, overweight/obesity, smoking, physical exercise, red meat intake, intake of fruits and vegetables, etc.
    (Image source: Reference [1]) "China Type 2 Diabetes Prevention Guidelines (2020 Edition) proposes that for more than half of patients with type 2 diabetes who have no obvious early clinical manifestations, diabetes screening (mainly a two-point method, namely fasting blood glucose + 75 g oral glucose tolerance test 2 h blood glucose) It can be "early detected and treated"
    .

    In addition, diabetes should adopt a comprehensive treatment strategy: while carrying out comprehensive interventions on blood sugar, blood pressure, blood lipids, body weight, etc.
    , HbA1c should be controlled within a reasonable personal goal
    .

    ▲China's type 2 diabetes comprehensive control target (picture source: reference [2]) Summary According to the latest research estimates, the incidence of adult diabetes in China is not only still high (reaching 12.
    4%; the global diabetes prevalence rate in 2019 is 8.
    3%) , And showing a growing trend
    .

    At the same time, diabetes awareness, treatment and control rates have been kept at a low level
    .

    As the overweight/obesity rate of the Chinese population is also not optimistic, based on the general impact of the overall population’s life>
    .

    The findings of this study have important clinical and public health implications
    .

    In view of the current "three lows" of diabetes patients in China, that is, the low awareness rate, low treatment rate, and low control rate, it is necessary for us to take comprehensive actions in the future to address the burden of diabetes from multiple perspectives such as health, economy, and society, and formulate More comprehensive, personalized and sustainable interventions
    .

    Related reading ADA's latest diabetes guidelines: It is recommended that everyone start screening at the age of 35.
    Metformin may not be the "first choice".
    .
    .
    1 person dies of diabetes every 5 seconds, and a quarter of the patients are in China! The latest Global Diabetes Map released the "two-pronged approach" for weight loss + hypoglycemia.
    Will the next breakthrough direction for diabetes treatment be "it"? |"Nature" Annual Review "The Lancet" Sub-Journal: Dapagliflozin reduces new-onset diabetes by 33%, and two key studies add more evidence of benefit! The number of "non-traditional" concurrent diseases among diabetic patients has increased dramatically! The 16-year data of the "Lancet" sub-journal reveals the change of the cause of hospitalization.
    Source: 123RF Reference Materials [1] Wang L, Peng W, Zhao Z, et al.
    Prevalence and Treatment of Diabetes in China, 2013-2018.
    JAMA.
    2021;326(24):2498–2506.
    doi:10.
    1001/jama.
    2021.
    22208[2] Chinese Medical Association Diabetes Branch.
    Chinese Type 2 Diabetes Prevention Guidelines (2020 Edition)[J].
    Chinese Journal of Diabetes,2021,13( 4):317-411.
    DOI:10.
    3760/cma.
    j.
    cn115791-20210221-00095.
    Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
    .

    This article is for the purpose of information exchange only.
    The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
    .

    This article is not a treatment recommendation either
    .

    If you need guidance on the treatment plan, please go to a regular hospital for treatment
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.